Brokers Issue Forecasts for Atossa Genetics Q3 Earnings

Atossa Genetics Inc. (NASDAQ:ATOS) – Stock analysts at Ascendiant Capital Markets boosted their Q3 2026 earnings per share (EPS) estimates for shares of Atossa Genetics in a research report issued on Wednesday, September 30th. Ascendiant Capital Markets analyst E. Woo now forecasts that the company will post earnings of ($0.78) per share for the quarter, up from their previous forecast of ($1.10). The consensus estimate for Atossa Genetics’ current full-year earnings is ($3.75) per share. Ascendiant Capital Markets also issued estimates for Atossa Genetics’ Q4 2026 earnings at ($0.78) EPS, FY2026 earnings at ($3.56) EPS, Q1 2027 earnings at ($0.83) EPS, Q2 2027 earnings at ($0.83) EPS, Q3 2027 earnings at ($0.83) EPS, Q4 2027 earnings at ($0.83) EPS and FY2027 earnings at ($3.30) EPS.

A number of other brokerages have also issued reports on ATOS. Rodman & Renshaw assumed coverage on Atossa Genetics in a research report on Tuesday, July 7th. They set a “buy” rating and a $12.00 target price on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Atossa Genetics in a report on Tuesday, September 8th. Finally, Wall Street Zen upgraded shares of Atossa Genetics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. Three investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat, Atossa Genetics has a consensus rating of “Hold” and a consensus price target of $20.33.

Atossa Genetics Stock Performance

Shares of ATOS opened at $2.45 on Tuesday. The firm has a market cap of $24.45 million, a P/E ratio of -0.79 and a beta of 1.27. Atossa Genetics has a 12 month low of $1.70 and a 12 month high of $19.35. The stock’s 50 day moving average is $2.39 and its two-hundred day moving average is $3.50.

Atossa Genetics (NASDAQ:ATOS) last released its quarterly earnings results on Friday, August 7th. The company reported ($0.95) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.07.

Hedge Funds Weigh In On Atossa Genetics

An institutional investor recently bought a new position in Atossa Genetics stock. State Street Corp purchased a new position in Atossa Genetics Inc. (NASDAQ:ATOS) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 39,761 shares of the company’s stock, valued at approximately $77,000. State Street Corp owned about 0.40% of Atossa Genetics at the end of the most recent reporting period. 12.74% of the stock is currently owned by institutional investors and hedge funds.

About Atossa Genetics

Atossa Genetics, Inc, now operating as Atossa Therapeutics, Inc (NASDAQ: ATOS), is a clinical-stage biopharmaceutical company focused on developing therapies for breast cancer and other diseases affecting breast tissue. The company’s research is centered on targeted treatments intended to address unmet needs in the prevention and treatment of breast cancer.

Atossa’s principal investigational product is oral endoxifen, a selective estrogen receptor modulator being evaluated in clinical studies involving patients with hormone receptor-positive breast cancer.